Skip to search formSkip to main contentSkip to account menu

NSC 601316

Known as: NSC-601316 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

DACA, acridine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2006
Highly Cited
2006
Gateways to clinical trials.
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2004
2004
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
1997
1997
Studies on the metabolism of the novel antitumor agent [N-methyl-11C]N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase I clinical trials.
This study reports on the biodistribution and metabolism of the 11C-labeled novel antitumor agent N-[2-(dimethylamino)ethyl… 
1994
1994
Methadone: a potent inhibitor of rat liver aldehyde oxidase.
1993
1993
Inhibition by SKF-525A of the aldehyde oxidase-mediated metabolism of the experimental antitumour agent acridine carboxamide.
1991
1991
Cytosol mediated metabolism of the experimental antitumor agent acridine carboxamide to the 9-acridone derivative.
1990
1990
Genetic toxicology of tricyclic carboxamides, a new class of DNA binding antitumour agent.
1989
1989
Selectivity of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide towards Lewis lung carcinoma and human tumour cell lines in vitro.
Highly Cited
1988
Highly Cited
1988
Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License